International Myeloma Foundation
MYELOMA MINUTE | Up To The Minute News | 8.19.2021
nurse meeting with elderly patient at home with mask
san diego rcw banner
Register Now for This Upcoming Multiple Myeloma Virtual Community Workshop
Do you have questions about myeloma that you would like to ask myeloma experts? Do you want information about the best treatment options at the time of diagnosis? Do you have concerns on how to manage side effects? Has your myeloma relapsed? Are you exploring maintenance therapy options, or are you curious about available clinical trials? All these questions and more will be covered in the IMF Virtual Regional Community Workshop on Saturday, August 28, at 7 a.m. PT / 10 a.m. ET.

The expert panel includes IMF Chief Medical Officer Joseph Mikhael, MD, M.Ed., FRCPC (TGen, City of Hope — Phoenix, AZ); Rafat Abonour, MD (Indiana University School of Medicine — Indianapolis); and IMF Nurse Leadership Board member Tiffany Richards, PhD, ANP-BC. Senior Director of IMF Regional Community Workshops Kelly Cox will welcome guests.
register button
patient family webinar with speakers
Watch Now to Learn How to Manage Your Myeloma and Prevent COVID-19
In this webinar, myeloma experts answer questions including: When to receive a COVID-19 booster shot? What are the first steps for newly diagnosed myeloma patients? How to manage side effects? What are the newest immune therapies, and what treatments should relapsed patients undergo?

IMF Chairman Dr. Brian G.M. Durie moderates presentations with myeloma experts Rafat Abonour, MD (Indiana University School of Medicine — Indianapolis); Noopur Raje, MD (Massachusetts General Hospital — Boston); and Kevin Brigle PhD, ANP (Virginia Commonwealth University, Massey Cancer Center — Richmond, VA). If you missed the live webinar, you can watch the replay now.
2020WatchNowButton.png
Living Well Financial Support Webinar headshots
Watch Now to Learn How to Get Financial Help for Myeloma Patients and Caregivers
In this video, a financial navigator, oncology social worker, and myeloma nurse tackle the tough finance-related questions myeloma patients encounter including: What should cancer patients do when they can no longer work? How to apply for federal disability benefits? What patient financial support options exist? How to discuss high copays with your healthcare team?

The speakers include IMF Nurse Leadership Board member Beth Faiman PhD, MSN, APRN-BC, AOCN®, FAAN; Oncology Social Worker Rebecca Zeiter, MSSA, LSW; and Financial Navigator Shontia Gamble, LSW. All the speakers are practicing in their fields at the Cleveland Clinic Taussig Cancer Institute.

If you missed the live webinar, you can watch the replay now.
2020WatchNowButton.png
EuroComm.jpg
European Commission Approves Abecma (Idecabtagene Vicleucel), the First Anti-BCMA CAR T-Cell Therapy for Relapsed and Refractory Multiple Myeloma
Today, August 19, 2021, in a press release from Bristol Myers Squibb, it was announced that "the European Commission (EC) has granted Conditional Marketing Authorization for Abecma (idecabtagene vicleucel; ide-cel), a first-in-class B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell immunotherapy, for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy."
2020ReadNowButton.png
hatfield hike banner
On the Home Stretch: Bill Hatfield Hikes the Appalachian Trail to Raise Funds to Find a Cure for Myeloma
Bill Hatfield returned to hiking the Appalachian Trail on April 17, 2021, to raise funds for the International Myeloma Foundation (IMF) along the way. The IMF is immensely grateful to Bill for his 2,200-mile journey on foot, which will reach its end on September 11, 2021. Over the course of the next three weeks, Bill asks that you cheer him to the end of the Appalachian Trail, and if you can, donate to the IMF.
2020LearnMoreButton.png
Philippe Moreau presentation at ASCO on CASSIOPEIA
Watch This Video from ASCO 2021 on Part 2 of the CASSIOPEIA Study
In this video, Dr. Philippe Moreau (University Hospital Hôtel-Dieu Nantes, France ) discusses the results of Part 2 of the CASSIOPEIA study.
2020WatchNowButton.png
490x245NovisGrant.png
Calling All Researchers: Submit Your Grant Applications
The Brian D. Novis Research Grants honor IMF founder Brian Novis, who succumbed to multiple myeloma in July of 1992. The grants are awarded to researchers working in the field of multiple myeloma and related disorders, including smoldering multiple myeloma (SMM), monoclonal gammopathy of undetermined significance (MGUS), and immunoglobulin-derived amyloidosis. The 2022 grants will support senior research projects with $80,000 each and junior research projects with $50,000 each. The deadline to submit the applications is October 1, 2021. 
2020ButtonApplyNow.png
ask doctor durie video image
#ASKDRDURIE | Dr. Durie's Weekly Web Video Series
This Week’s Question:

Should myeloma patients get a COVID-19 booster shot?
Watch Now
 
Clinical Trial Fact Sheets

Smart Patients: Join the Conversation

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)
Upcoming Events & Replays
Register Now
Miracles for Myeloma Virtual Run/Walk

Watch the Replay
“Living Well with Myeloma” Webinar on Nutrition

Watch the Replay
M-Power Charlotte Community Workshop

Click here to see all events
 

We Thank Our Sponsors:

Amgen, Bristol Myers Squibb, Karyopharm Therapeutics, Oncopeptides Inc.,
Sanofi-Genzyme, and Takeda Oncology
We also thank individuals like you for your continued support!
Subscribe Button@2x.jpg
2020ButtonDonateBurg.png
Join the conversation at The International Myeloma Foundation
Facebook Facebook: /Myeloma  |  Twitter Twitter @IMFMyeloma  |  Instagram Instagram @IMFmyeloma

www.myeloma.org
This email was sent by:
The International Myeloma Foundation
12650 Riverside Drive, Suite 206
North Hollywood, CA 91607-3421
Connect with the IMF InfoLine
1-800-452-2873
We respect your privacy and your preferences for communications of this nature.
Home  •  Unsubscribe  •  Privacy Policy
View as web page